Recite me link

Q1. How many patients were treated in October 2021 (or latest available month) by the gastroenterology department with the following drugs:
a. Adalimumab (any brand or biosimilar)
b. Infliximab (any brand or biosimilar)
c. Ustekinumab (Stelara)
d. Vedolizumab (Entyvio)
e. Tofacitinib (Xeljanz)
f. Filgotinib (Jyseleca)
Q2. How many patients were treated in October 2021 (or latest available month) for Crohn’s Disease ONLY with the following drugs:
a. Adalimumab (any brand or biosimilar)
b. Infliximab (any brand or biosimilar)
c. Ustekinumab (Stelara)
d. Vedolizumab (Entyvio)

Download response Biologic medications in gastroenterology. 040122.docx